Rituximab Linked to Tenfold Risk Increase for Inflammatory Bowel Disease in MS Patients
Patients with relapsing-remitting multiple sclerosis treated with the anti-CD20 medication rituximab face roughly ten times the risk of developing inflammatory bowel disease compared to those taking other high-efficacy disease-modifying therapies, researchers reported in a new population-based study. Despite the relative risk increase, the absolute risk remains low, with fewer than two percent of patients across all treatment groups developing the condition within a decade of starting treatment.
Swedish Registry Data Compares Four MS Treatments
Investigators analyzed nearly 14,000 treatment episodes among individuals with relapsing-remitting multiple sclerosis using data drawn from Swedish registers. The study evaluated rituximab against three alternative high-efficacy multiple sclerosis medications: natalizumab, dimethyl fumarate, and fingolimod. Inflammatory bowel disease appeared more frequently among patients receiving rituximab than among the comparison groups, even after researchers adjusted for the duration of patient follow-up and other underlying differences between the cohorts. The risk escalation translates to roughly one extra case for every 131 patients treated with rituximab for five years instead of an alternative medication, with the majority of those cases identified as Crohn’s disease.
Frequently Asked Questions About MS Therapy and Bowel Health
Why did neurologists initiate this registry investigation?
As anti-CD20 treatments became increasingly common across Sweden, clinicians reported individual cases of patients developing inflammatory disease while on the medication, prompting concern that lacked backing from larger epidemiological studies until now.
Which specific alternative medications served as benchmarks in the study?
Researchers compared rituximab outcomes against natalizumab, dimethyl fumarate, and fingolimod to establish how the risk profiles differed among available high-efficacy multiple sclerosis therapies.
What specific form of inflammatory bowel disease accounted for most diagnoses?
The majority of the inflammatory bowel disease cases identified in the patient registries consisted of Crohn’s disease.
- Maynooth University Study Finds Bariatric Surgery Reverses Obesity Immune Defects
- First-in-World Procedure Provides Relief for “Suicide Disease” Patient
- Study: Moderate-strength tea may lower vascular disease risk by 11% (archyworldys.com)
- Patients may use structured nutrition and movement for AML recovery (archyde.com)